GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy

Chien Yu Lin, Ting Yang Lin, Hung Ming Wang, Shiang Fu Huang, Kang Hsing Fan, Chun Ta Liao, I. How Chen, Li Yu Lee, Yen Liang Li, Yin Ju Chen, Ann Joy Cheng, Joseph T. Chang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Oral cavity cancers (ORC) are the most common cancers, and standard treatment is radical surgery with postoperative radiotherapy. However, locoregional failure remains a major problem, indicating radioresistance an important issue. Our previous work has shown that GP96 contributed to radioresistance in nasopharyngeal and oral cancer cell lines. In this study, we determined clinical significance of GP96 in ORC by evaluation of GP96 expression and its association with disease prognosis in patients receiving radiotherapy. Methods: Total of 79 ORC patients (77 males, median age: 48 years old) receiving radical surgery and postoperative radiotherapy between Oct 1999 and Dec 2004 were enrolled. Patients in pathological stages II, III and IV were 16.5%, 16.5% and 67%, respectively. For each patient, a pair of carcinoma tissue and grossly adjacent normal mucosa was obtained. GP96-expression was examined by western blot analysis, and the association with clinicopathological status was determined.Results: Three-year locoregional control (LRC), distant metastasis-free survival (DMFS), disease-specific survival (DSS) and overall survival (OS) rates were 69%, 79%, 63% and 57%, respectively. We found that 55 patients (70%) displayed GP96-overexpression in the tumor tissue, which correlated with a higher pN stage (p = 0.020) and tumor depth (> 10 mm) (p = 0.045). Nodal extracapsular spreading (ECS) and GP96-overexpression predicted adverse LRC (p = 0.049 and p = 0.008). When stratified by nodal ECS, the adverse impact of GP96 remained significant in three-year LRC (p = 0.004). In multivariate analysis, GP96-overexpression was also an independent predictor of LRC, DSS and OS (p = 0.018, p = 0.011 and p = 0.012).Conclusion: GP96 may play roles in radioresistance which attributes to tumor invasiveness in oral cancer patients receiving radiotherapy. GP96 may serve as a novel prognostic marker of radiotherapy. However, further independent studies are required to validate our findings in a larger series.

Original languageEnglish
Article number136
JournalRadiation Oncology
Volume6
Issue number1
DOIs
Publication statusPublished - Oct 12 2011
Externally publishedYes

Fingerprint

Mouth Neoplasms
Mouth
Radiotherapy
Survival
Neoplasms
Nasopharyngeal Neoplasms
Disease-Free Survival
Mucous Membrane
Multivariate Analysis
Survival Rate
Western Blotting
Neoplasm Metastasis
Carcinoma
Cell Line

Keywords

  • Gp96
  • Oral cavity cancers
  • Prognosis
  • Radioresistance

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Lin, C. Y., Lin, T. Y., Wang, H. M., Huang, S. F., Fan, K. H., Liao, C. T., ... Chang, J. T. (2011). GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy. Radiation Oncology, 6(1), [136]. https://doi.org/10.1186/1748-717X-6-136

GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy. / Lin, Chien Yu; Lin, Ting Yang; Wang, Hung Ming; Huang, Shiang Fu; Fan, Kang Hsing; Liao, Chun Ta; Chen, I. How; Lee, Li Yu; Li, Yen Liang; Chen, Yin Ju; Cheng, Ann Joy; Chang, Joseph T.

In: Radiation Oncology, Vol. 6, No. 1, 136, 12.10.2011.

Research output: Contribution to journalArticle

Lin, CY, Lin, TY, Wang, HM, Huang, SF, Fan, KH, Liao, CT, Chen, IH, Lee, LY, Li, YL, Chen, YJ, Cheng, AJ & Chang, JT 2011, 'GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy', Radiation Oncology, vol. 6, no. 1, 136. https://doi.org/10.1186/1748-717X-6-136
Lin, Chien Yu ; Lin, Ting Yang ; Wang, Hung Ming ; Huang, Shiang Fu ; Fan, Kang Hsing ; Liao, Chun Ta ; Chen, I. How ; Lee, Li Yu ; Li, Yen Liang ; Chen, Yin Ju ; Cheng, Ann Joy ; Chang, Joseph T. / GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy. In: Radiation Oncology. 2011 ; Vol. 6, No. 1.
@article{0d776ec5baeb49898b0e20c46ea8d895,
title = "GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy",
abstract = "Background: Oral cavity cancers (ORC) are the most common cancers, and standard treatment is radical surgery with postoperative radiotherapy. However, locoregional failure remains a major problem, indicating radioresistance an important issue. Our previous work has shown that GP96 contributed to radioresistance in nasopharyngeal and oral cancer cell lines. In this study, we determined clinical significance of GP96 in ORC by evaluation of GP96 expression and its association with disease prognosis in patients receiving radiotherapy. Methods: Total of 79 ORC patients (77 males, median age: 48 years old) receiving radical surgery and postoperative radiotherapy between Oct 1999 and Dec 2004 were enrolled. Patients in pathological stages II, III and IV were 16.5{\%}, 16.5{\%} and 67{\%}, respectively. For each patient, a pair of carcinoma tissue and grossly adjacent normal mucosa was obtained. GP96-expression was examined by western blot analysis, and the association with clinicopathological status was determined.Results: Three-year locoregional control (LRC), distant metastasis-free survival (DMFS), disease-specific survival (DSS) and overall survival (OS) rates were 69{\%}, 79{\%}, 63{\%} and 57{\%}, respectively. We found that 55 patients (70{\%}) displayed GP96-overexpression in the tumor tissue, which correlated with a higher pN stage (p = 0.020) and tumor depth (> 10 mm) (p = 0.045). Nodal extracapsular spreading (ECS) and GP96-overexpression predicted adverse LRC (p = 0.049 and p = 0.008). When stratified by nodal ECS, the adverse impact of GP96 remained significant in three-year LRC (p = 0.004). In multivariate analysis, GP96-overexpression was also an independent predictor of LRC, DSS and OS (p = 0.018, p = 0.011 and p = 0.012).Conclusion: GP96 may play roles in radioresistance which attributes to tumor invasiveness in oral cancer patients receiving radiotherapy. GP96 may serve as a novel prognostic marker of radiotherapy. However, further independent studies are required to validate our findings in a larger series.",
keywords = "Gp96, Oral cavity cancers, Prognosis, Radioresistance",
author = "Lin, {Chien Yu} and Lin, {Ting Yang} and Wang, {Hung Ming} and Huang, {Shiang Fu} and Fan, {Kang Hsing} and Liao, {Chun Ta} and Chen, {I. How} and Lee, {Li Yu} and Li, {Yen Liang} and Chen, {Yin Ju} and Cheng, {Ann Joy} and Chang, {Joseph T.}",
year = "2011",
month = "10",
day = "12",
doi = "10.1186/1748-717X-6-136",
language = "English",
volume = "6",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy

AU - Lin, Chien Yu

AU - Lin, Ting Yang

AU - Wang, Hung Ming

AU - Huang, Shiang Fu

AU - Fan, Kang Hsing

AU - Liao, Chun Ta

AU - Chen, I. How

AU - Lee, Li Yu

AU - Li, Yen Liang

AU - Chen, Yin Ju

AU - Cheng, Ann Joy

AU - Chang, Joseph T.

PY - 2011/10/12

Y1 - 2011/10/12

N2 - Background: Oral cavity cancers (ORC) are the most common cancers, and standard treatment is radical surgery with postoperative radiotherapy. However, locoregional failure remains a major problem, indicating radioresistance an important issue. Our previous work has shown that GP96 contributed to radioresistance in nasopharyngeal and oral cancer cell lines. In this study, we determined clinical significance of GP96 in ORC by evaluation of GP96 expression and its association with disease prognosis in patients receiving radiotherapy. Methods: Total of 79 ORC patients (77 males, median age: 48 years old) receiving radical surgery and postoperative radiotherapy between Oct 1999 and Dec 2004 were enrolled. Patients in pathological stages II, III and IV were 16.5%, 16.5% and 67%, respectively. For each patient, a pair of carcinoma tissue and grossly adjacent normal mucosa was obtained. GP96-expression was examined by western blot analysis, and the association with clinicopathological status was determined.Results: Three-year locoregional control (LRC), distant metastasis-free survival (DMFS), disease-specific survival (DSS) and overall survival (OS) rates were 69%, 79%, 63% and 57%, respectively. We found that 55 patients (70%) displayed GP96-overexpression in the tumor tissue, which correlated with a higher pN stage (p = 0.020) and tumor depth (> 10 mm) (p = 0.045). Nodal extracapsular spreading (ECS) and GP96-overexpression predicted adverse LRC (p = 0.049 and p = 0.008). When stratified by nodal ECS, the adverse impact of GP96 remained significant in three-year LRC (p = 0.004). In multivariate analysis, GP96-overexpression was also an independent predictor of LRC, DSS and OS (p = 0.018, p = 0.011 and p = 0.012).Conclusion: GP96 may play roles in radioresistance which attributes to tumor invasiveness in oral cancer patients receiving radiotherapy. GP96 may serve as a novel prognostic marker of radiotherapy. However, further independent studies are required to validate our findings in a larger series.

AB - Background: Oral cavity cancers (ORC) are the most common cancers, and standard treatment is radical surgery with postoperative radiotherapy. However, locoregional failure remains a major problem, indicating radioresistance an important issue. Our previous work has shown that GP96 contributed to radioresistance in nasopharyngeal and oral cancer cell lines. In this study, we determined clinical significance of GP96 in ORC by evaluation of GP96 expression and its association with disease prognosis in patients receiving radiotherapy. Methods: Total of 79 ORC patients (77 males, median age: 48 years old) receiving radical surgery and postoperative radiotherapy between Oct 1999 and Dec 2004 were enrolled. Patients in pathological stages II, III and IV were 16.5%, 16.5% and 67%, respectively. For each patient, a pair of carcinoma tissue and grossly adjacent normal mucosa was obtained. GP96-expression was examined by western blot analysis, and the association with clinicopathological status was determined.Results: Three-year locoregional control (LRC), distant metastasis-free survival (DMFS), disease-specific survival (DSS) and overall survival (OS) rates were 69%, 79%, 63% and 57%, respectively. We found that 55 patients (70%) displayed GP96-overexpression in the tumor tissue, which correlated with a higher pN stage (p = 0.020) and tumor depth (> 10 mm) (p = 0.045). Nodal extracapsular spreading (ECS) and GP96-overexpression predicted adverse LRC (p = 0.049 and p = 0.008). When stratified by nodal ECS, the adverse impact of GP96 remained significant in three-year LRC (p = 0.004). In multivariate analysis, GP96-overexpression was also an independent predictor of LRC, DSS and OS (p = 0.018, p = 0.011 and p = 0.012).Conclusion: GP96 may play roles in radioresistance which attributes to tumor invasiveness in oral cancer patients receiving radiotherapy. GP96 may serve as a novel prognostic marker of radiotherapy. However, further independent studies are required to validate our findings in a larger series.

KW - Gp96

KW - Oral cavity cancers

KW - Prognosis

KW - Radioresistance

UR - http://www.scopus.com/inward/record.url?scp=80053903699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053903699&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-6-136

DO - 10.1186/1748-717X-6-136

M3 - Article

C2 - 21992474

AN - SCOPUS:80053903699

VL - 6

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 136

ER -